The 1st Kuwait Familial Hypercholesterolemia Symposium, the 4th IAS Severe FH Master Class, and the IAS/ASPED Pediatric FH Satellite is targeted to meet the educational needs of medical professionals in clinical practice engaged in the prevention or the management of patients demonstrating risk or with established cardiovascular disease
Upon completion of this program participants should be able to:
1) Recognize, diagnose, and treat severe familial hypercholesterolemia (both HeFH and HoFH) in accordance with current guidelines.
2) Discuss the implications of family history, consanguinity, and cascade screening.
3) Discuss the complications of familial hypercholesterolemia.
4) Discuss HoFH and pregnancy.
5) Discuss HoFH and COVID-19.
6) Outline the clinical indications of LDL apheresis.
7) Evaluate the efficacy, safety, and tolerability of various drugs for the treatment of severe familial hypercholesterolemia to implement appropriately targeted treatment plans.
8) Diagnosis and management of pediatric HeFH and HoFH.
9) Work collaboratievely to analyze and discuss several case studies.
The IAS is proud to present this esteemed global faculty. More information on each faculty member can be found by clicking on their name.
Disclosures | Date of Disclosures |
Consulting/Speaking/Research activities from: Akcea, Amgen, AstraZeneca, Biolab, Esperion, Kowa, Merck, Novo-Nordisk, Pfizer, and Sanofi/Regeneron. | 26-02-2021 |
Disclosures | Date of Disclosures |
Consulting/Speaking/Research activities from: Akcea, Amgen, AstraZeneca, Biolab, Esperion, Kowa, Merck, Novo-Nordisk, Pfizer, and Sanofi/Regeneron. | 26-02-2021 |
Disclosures | Date of Disclosures |
Consulting/Speaking/Research activities from: Akcea, Amgen, AstraZeneca, Biolab, Esperion, Kowa, Merck, Novo-Nordisk, Pfizer, and Sanofi/Regeneron. | 26-02-2021 |
Disclosures | Date of Disclosures |
Honoraria for advisory boards: Sanofi, Amgen. Speaker fees: Sanofi, Amgen, Amryt, Novartis, Abbott. Clinical trials – Payments to Institution: Amgen, Sanofi, Regeneron, Novartis. | 26-02-2021 |
Disclosures | Date of Disclosures |
Speaker fees: Amgen, Amryt. Clinical trials – Payment to Institution: Amryt | 26-02-2021 |
There are no Disclosure Statements for Dr. Deeb
There are no Disclosure Statements for Dr. Al Sarraf
There are no Disclosure Statements for Dr. Wiegman
There are no Disclosure Statements for Dr. Ben-Omran
There are no Disclosure Statements for Dr. Al Rajhi
There are no Disclosure Statements for Dr. Maatouk
Staff Disclosures
Staff involved with the development of this activity have nothing to disclose.by clicking on their
The IAS is very grateful to Amryt Pharma, Amgen, Kaneka, Sanofi and AAW for supporting the 1st Kuwait Familial Hypercholesterolemia Symposium & 4th Severe FH Masterclass through an unrestricted educational grant. We also thank all the faculty and clinician attendees who shared their experience and contributed to the IAS in its global mission.